R&D Sponsored Company Profile: Recursion TechBio Recursion is continuously moving toward increased AI, automation, and machine learning modelling.
Digital A look back at 2023: A Benchling biotech breakfast As we enter the New Year, and set forth into the myriad possibilities and plans of 2024, it pays to pause and reflect.
R&D Talking techbio with NVIDIA: Accelerated computing, NLP, and... As Genentech and NVIDIA enter into a multi-year strategic AI research collaboration to accelerate drug discovery and development, web editor Nicole Raleigh revisits a recent discussion with
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
